Sobi receives FDA breakthrough designation for hemophilia drug
The US health authority has now awarded the Swedish firm three special statuses – the orphan drug, fast-track, and breakthrough therapy designations – for its hemophilia A treatment.
by christian bundgaard, translated by daniel pedersen
Swedish biotech firm Sobi has been granted the US Food and Drug Administration’s (FDA) breakthrough therapy designation for its drug candidate, efanesoctocog alfa, a potential treatment for bleeding disorder hemophilia A, the company has announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
